ASRS 2020 Annual Meeting | July 2020

Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Choroidal Neovascularization in AMD (ForeseeHome Device)

Allen Ho, MD
ARVO 2018 Annual Meeting | May 2018

Comparison of fluorescein angiographic evaluation of the lesion size of choroidal neovascularization associated with age-related macular degeneration in participants and non-participants of the home tele-monitoring study (ForeseeHome Study)

Ramiro S. Maldonado, Elvira Agron, Traci E. Clemons, Emily Y. Chew

Home telemonitoring device strategy resulted in smaller lesions of CNV than the other two groups. This early detection was associated with better visual acuity and may represent better visual outcomes following therapy for participants in the telemonitoring group.

32nd Annual Meeting of the American Society of Retina Specialists | August 2014

Lesion Characteristics of Early Choroidal Neovascularization. The HOME Study: ForeseeHome® in AREDS2

Judy E. Kim

The HOME study demonstrated that the distribution of lesion characteristics and visual acuity at the time of CNV detection in patients randomly assigned to the home device in addition to standard care is highly favorable. These attributes will likely lead to improved vision outcome following anti-VEGF treatment.

ARVO 2014 Annual Meeting | April 2014

The Home Monitoring of the Eye (HOME) Study: Potential implication of Findings on Management of Intermediate AMD Patients

Alexander J Brucker; AREDS II - HOME STUDY

Persons at high risk for CNV benefit from the home monitoring strategy for earlier detection of CNV. The productivity of an office visit prompted by a device alert is far greater than a routine office visit in identifying new onset CNV.

ARVO 2014 Annual Meeting | April 2014

Qualifying to Use a Preferential Hyperacuity Perimetry Home Device Prior to Monitoring for Neovascular Age-related Macular Degeneration

Merina Thomas; Yulia Wolfson; Voraporn Chaikitmongkol; Susan B Bressler; Neil M Bressler

The data suggests that most patients who have the intermediate stage of AMD should produce a reliable test when first using a home device PHP and between 61% to 77% likely will pass a qualification test to initiate at home monitoring, among whom 88% to 99% likely will establish a baseline after 5 at-home tests to permit monitoring for progression to neovascular AMD.

Media enquiries? Reach out to our Media Contact